Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 19Gastrointestinal 14Dermatologic 10Other solid neoplasm 7CNS 4Breast 4Tumor-Agnostic 3Head & Neck 3Sarcoma 2Endocrine 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × AZD 6244 × Tumor-Agnostic × Clear all
NCT03745989 2023-07-27

MK-8353-014

Merck Sharp & Dohme LLC

Phase 1 Completed
30 enrolled 19 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

AstraZeneca

Phase 1 Completed
48 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

AstraZeneca

Phase 1 Completed
21 enrolled 4 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡